Update: See our article discussing notable points from the Draft Guidelines.
Following its Phase 2 Consultations, on December 19, 2024, the Patented Medicine Prices Review Board (PMPRB) released its new Draft Guidelines and accompanying Overview. The deadline for providing submissions on the Draft Guidelines is March 19, 2025. The PMPRB continues to plan to release its final Guidelines in 2025.
Should you have any questions, please do not hesitate to contact a member of the Life Sciences Regulatory & Compliance Group.
The preceding is intended as a timely update on Canadian intellectual property and life sciences law. The content is informational only and does not constitute legal or professional advice. To obtain such advice, please communicate with our offices directly.
Related Publications & Articles
-
CDA releases strategy to improve the appropriate prescribing and use of prescription medications in Canada
On September 18, 2025, Canada’s Drug Agency (CDA) launched its new strategy to improve the appropriate prescribing and use of prescription medications in Canada.Read More -
PMPRB releases Annual Public Drug Plan Expenditure Report (2022/23)
On October 21, 2025, the Patented Medicine Prices Review Board (PMPRB) announced the release of CompassRx, an annual report that analyzes factors driving prescription drug expenditures in Canadian pub...Read More -
Ontario pilot program and pCPA new negotiation pathway aim to expedite access to breakthrough cancer treatments
The Ontario government and the pan-Canadian Pharmaceutical Alliance (pCPA) announced separate initiatives in October 2025, both aimed to accelerate patient access to breakthrough cancer treatments app...Read More
